Early Anticoagulation in Acute Ischemic Stroke With Atrial Fibrillation.

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Patients with atrial fibrillation (AF) experiencing acute ischemic stroke (AIS) face a high risk of recurrent stroke or embolism.
• Balancing anticoagulation for stroke prevention against hemorrhage risk is critical.
• Traditional anticoagulants (heparin, VKAs) have shown uncertain benefits for early AIS treatment.

Purpose of the Study:

• To evaluate the safety and efficacy of early non-vitamin K oral anticoagulant (NOAC) initiation in AIS patients with AF.
• To synthesize evidence from randomized controlled trials and meta-analyses on early NOAC therapy.

Main Methods:

• Review of randomized controlled trials (RCTs) and individual patient data meta-analyses.
• Analysis of safety and efficacy outcomes, including recurrent stroke, embolism, and bleeding events.

Main Results:

• Early NOAC initiation is confirmed as safe and effective, surpassing historical anticoagulation uncertainties.
• Observational studies initially suggested NOAC benefits, now robustly supported by RCTs and meta-analyses.

Conclusions:

• Early anticoagulation with NOACs is recommended for AIS patients with AF to prevent secondary events.
• Further research is needed for specific populations like those with severe stroke, hemorrhagic transformation, or Asian ethnicity due to increased bleeding risk and underrepresentation in trials.